Views

WHITE PAPER – Biotech and Breakthroughs in Immuno-Oncology

WHITE PAPER – Biotech and Breakthroughs in Immuno-Oncology

Key Points

  • Paradigm-shift in disease management with the approval of immuno-oncology agents, namely, checkpoint inhibitors, created a major shift in how patients with cancers are treated.
  • The significant clinical impact of checkpoint inhibitors led to what some have seen as a goldrush, others as a bubble, toward clinical development of immunotherapies.
  • Immuno-oncology agents have not by and large cured most patients in most cancers, hence new immunotherapeutic agents and combinations are needed.
  • Over the past 5 years, much of the BioPharma industry’s focus has been on expanding the range of immuno-oncology agents and combinations.

Complete the information below to download your free copy of the White Paper

For further information about our range of services

Contact Us

Share this

Related Articles

Alzheimer’s and Dementia: A Snapshot of the Science and Shape of the Future
10 January 2022
Alzheimer’s and Dementia: A Snapshot of the Science and Shape of the Future

Read our interview on Alzheimer’s and dementia with Dr. Ashby, who leads a research group within the School of Physiology, Pharmacology and Neuroscience at the University of Bristol by completing the form below.

Sonar – your ‘finger on the pulse’ in the digital space
18 November 2021
Sonar – your ‘finger on the pulse’ in the digital space

Introducing Sonar – a new syndicated offer from Cello Health

Cello Health Announces New Syndicated Research Program
12 November 2021
Cello Health Announces New Syndicated Research Program

Cello Health has developed a suite of syndicated offerings tailored to support your strategic objectives at key stages in the product lifecycle. Our customizable group of reports will provide regular actionable insights from market landscape maps based on social media data, as well as ongoing tracking of HCP preferences and channel behavior.

The US Forecaster’s Check List for Japan: A World of Difference
24 September 2021
The US Forecaster’s Check List for Japan: A World of Difference

The US Forecaster’s Check List for Japan: A World of Difference

Expanding the valuation of a biopharmaceutical asset to Japan requires a new mindset in nearly every input of forecasting, with many pitfalls. Doug Willson, Senior Vice President, Cello Health Advantage and Tiffany Ahlers, Chief Commercial Officer, Mycovia Pharmaceuticals Inc., share a checklist to improve the rigor and validity of product forecasts for Japan.

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us